DMAA Rapid is an oral stimulant from Knoll Pharmaceuticals delivering 50 mg of 1,3-Dimethylamylamine (DMAA) per tablet. The product is aimed at athletes in a bodybuilding context who want targeted support for focus, energy availability and thermogenic effect before training.
DMAA Rapid is a precisely dosed stimulant preparation by Knoll Pharmaceuticals, providing the active substance 1,3-dimethylamylamine (DMAA) in a standardized single dose of 50 mg per tablet.
| Phase | Dose | Timing | Notes |
|---|---|---|---|
| Introduction (Weeks 1–2) | 50 mg (1 tablet) | 30–45 min before training | Assess individual tolerability; no second daily dose |
| Maintenance (Weeks 3–6) | 50 mg (1 tablet) | 30–45 min before training | Do not use on rest days |
| Combination (thermogenic) | 50 mg DMAA + companion compound | Simultaneous intake possible | Heart rate and blood pressure monitoring mandatory |
| Maximum dose | 50 mg/day | Do not exceed | No accumulation; at least 24 h between doses |
| Break | — | At least 4 weeks off after 6 weeks of use | Avoid tolerance build-up; minimise receptor downregulation |
DMAA Rapid is a precisely dosed stimulant preparation from Knoll Pharmaceuticals, providing the active compound 1,3-Dimethylamylamine (DMAA) in a standardised single dose of 50 mg per tablet.
1,3-Dimethylamylamine is a sympathomimetic amine with structural similarities to endogenous catecholamines. DMAA inhibits the reuptake of noradrenaline and dopamine at presynaptic nerve terminals while simultaneously stimulating their release. This dual mechanism increases the concentration of both neurotransmitters in the synaptic cleft, resulting in heightened adrenergic activity that manifests in a training context as increased mental focus, greater alertness and enhanced sympathoadrenergic activation. The thermogenic component arises from an elevated basal metabolic rate driven by catecholaminergic stimulation of brown adipose tissue, alongside a moderate increase in blood pressure and heart rate.
DMAA Rapid tablets are manufactured under GMP-compliant production conditions. Active-ingredient concentration is verified by HPLC analysis to 50 mg ± 5 % per unit, ensuring reproducible dosing.
Athletes typically take DMAA Rapid 30–45 minutes before training to enhance subjective training intensity and psychomotor activation. DMAA has been studied in various contexts within strength and endurance sports since the 1940s, and its efficacy as a central stimulant is documented in the specialist literature. The 50 mg single dose represents a clearly defined unit in athletic practice, allowing for individual dose adjustment.
DMAA Rapid is frequently combined with thermogenic compounds such as Clenbuterol, Yohimbine or Salbutamol to achieve synergistic effects on lipolysis and sympathoadrenergic stimulation. Such combinations require a heightened degree of personal responsibility, a thorough understanding of pharmacokinetics and careful monitoring of heart rate and blood pressure.
Each pack of DMAA Rapid contains 30 tablets with 50 mg DMAA free base per tablet. The oral tablet form ensures a defined release profile and makes precise dose management easier than powder formats. Knoll Pharmaceuticals uses inert, standardised excipients during manufacture to minimise interactions with the active compound. The 30-tablet pack size corresponds to a typical training cycle of four to six weeks at the recommended frequency of use.
Knoll Pharmaceuticals is a manufacturer specialising in performance-oriented supplementation, producing its products under GMP-compliant conditions. DMAA Rapid exemplifies the company's focus on clearly defined single-compound preparations with verified active-ingredient concentrations. Knoll Pharmaceuticals relies on instrumental analytical methods such as HPLC to ensure purity and dosing accuracy, and directs its formulations at experienced athletes seeking controlled, reproducible stimulant supplementation.
| Brand | Knoll Pharmaceuticals |
|---|---|
| Active ingredient | 1,3-dimethylamylamine |
| Also known as | DMAA, 1, 3-DMAA, Methylhexanamin, Geranamin, DMAA Rapid, Knoll Pharmaceuticals DMAA |
| Strength | 50 mg |
| Form | Tabletten |
| Pack size | 30 pieces |
| Item number | OTHER-DMAA-KNO-001 |
No reviews yet. Be the first to review this product.
Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.
Pro ChoiceTAD 600 is an injectable glutathione preparation containing 600 mg reduced L-glutathione per 4 ml vial, manufactured by Biomedica Foscama. It supports hepatoprotective processes, promotes cellular detoxification and acts as a potent endogenous antioxidant – particularly relevant under elevated liver stress caused by anabolic substances. ---
Practitioner RecommendedReusable Pen is a reusable, mechanical injection device for standard 3 ml cartridges, enabling precise, incremental dosing of peptides, HGH and other active substances. The device features an integrated needle guard, is designed for multiple uses and meets the hygiene requirements of the medical profession.
Pairs well with these products.
High ConcentrationQuant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.
Long-Acting FormulaBolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.
Brand QualityEquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.
Pro ChoiceDragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.